Sign up to receive our personalized investment offer.

6.3% profit on AstraZeneca in our downtrend view


Drugmakers AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids while keeping the condition in check in a late-stage trial.

AstraZeneca PLC 20201202 10.28

Our information/charts are NOT buy/sell recommendations. Are strictly provided for educational purposes only. Trade at your own risk and analysis.
Subscribe now to our exclusive trading global stocks signals
Contact our advisors through website chat 24/7.



download follow on googleplus twitter2

Sign up to receive a personalized investment offer.